SCHEMBL577322

SCHEMBL577322

C#CCOS(=O)(=O)C(F)(F)F

nearest known ligand 0.35

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
CA2 P00918 4/20 0.35
CA1 P00915 2/20 0.33
ACHE P22303 1/20 0.32
CA9 Q16790 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL576681 0.86 ACHE (0.31) CA2ACHECA9
SCHEMBL14053029 0.86 CA2 (0.31) CA2
SCHEMBL14052987 0.82 CA1 (0.34) CA2CA1
SCHEMBL17596857 0.81 TSHR (0.40) CA2CA1CA9
SCHEMBL14052643 0.80 CA1 (0.33) CA2CA1
SCHEMBL14052877 0.78 CA1 (0.32) CA2CA1
SCHEMBL23415589 0.78 TSHR (0.31)
SCHEMBL17222829 0.78 CA2 (0.36) CA2CA1CA9
SCHEMBL3785941 0.77 CA2 (0.54) CA2CA1CA9
SCHEMBL14053458 0.77 CA1 (0.31) CA2CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 122 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12582634-B2 Synthetic methods for preparation of 4-(2-chloro-4-methoxy-5-methylphenyl)-n-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-n-prop-2-ynyl-1,3-thiazol-2-amine NEUROCRINE BIOSCIENCES, INC. (US) 2026-03-24 US claimed
US-20230286932-A1 SYNTHETIC METHODS FOR PREPARATION OF 4-(2-CHLORO-4-METHOXY-5-METHYLPHENYL)-N-[(1S)-2-CYCLOPROPYL-1-(3-FLUORO-4-METHYLPHENYL)ETHYL]-5-METHYL-N-PROP-2-YNYL-1,3-THIAZOL-2-AMINE NEUROCRINE BIOSCIENCES, INC. 2023-09-14 US claimed
CN-115087647-A Synthetic method for preparing 4- (2-chloro-4-methoxy-5-methylphenyl) -N- [ (1S) -2-cyclopropyl-1- (3-fluoro-4-methylphenyl) ethyl ] -5-methyl-N-prop-2-alkynyl-1, 3-thiazol-2-amine 纽罗克里生物科学有限公司 2022-09-20 CN claimed
CN-114890859-A Preparation method of 1, 4-pentadiyne compound 盐城工学院 2022-08-12 CN claimed
WO-2021111179-A1 SYNTHETIC METHOD FOR PREPARATION OF 4-(2-CHLORO-4-METHOXY-5-METHYLPHENYL)-N-[(1S)-2-CYCLOPROPYL-1-(3-FLUORO-4-METHYLPHENYL)ETHYL]-5-METHYL-N-PROP-2-YNYL-1,3-THIAZOL-2-AMINE NEUROCRINE BIOSCIENCES, INC. (US) 2021-06-10 WO claimed
US-12582634-B2 Synthetic methods for preparation of 4-(2-chloro-4-methoxy-5-methylphenyl)-n-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-n-prop-2-ynyl-1,3-thiazol-2-amine NEUROCRINE BIOSCIENCES, INC. (US) 2026-03-24 US disclosed
CN-119852515-A Electrolyte additive, electrolyte, battery and electricity utilization device 广州天赐高新材料股份有限公司 2025-04-18 CN disclosed
US-12128033-B2 Synthetic methods for preparation of 4-(2-chloro-4-methoxy-5-methylphenyl)-n-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-n-prop-2-ynyl-1,3-thiazol-2-amine NEUROCRINE BIOSCIENCES, INC. (US) 2024-10-29 US disclosed
US-20240297344-A1 NONAQUEOUS ELECTROLYTE FOR SECONDARY BATTERY AND NONAQUEOUS-ELECTROLYTE SECONDARY BATTERY EMPLOYING THE SAME MITSUBISHI CHEMICAL CORPORATION (JP) 2024-09-05 US disclosed
US-20240238257-A1 SYNTHETIC METHODS FOR PREPARATION OF 4-(2-CHLORO-4-METHOXY-5-METHYLPHENYL)-N-[(1S)-2-CYCLOPROPYL-1-(3-FLUORO-4-METHYLPHENYL)ETHYL]-5-METHYL-N-PROP-2-YNYL-1,3-THIAZOL-2-AMINE SANOFI (FR) 2024-07-18 US disclosed
US-20230286932-A1 SYNTHETIC METHODS FOR PREPARATION OF 4-(2-CHLORO-4-METHOXY-5-METHYLPHENYL)-N-[(1S)-2-CYCLOPROPYL-1-(3-FLUORO-4-METHYLPHENYL)ETHYL]-5-METHYL-N-PROP-2-YNYL-1,3-THIAZOL-2-AMINE NEUROCRINE BIOSCIENCES, INC. 2023-09-14 US disclosed
EP-3663305-B1 METHOD FOR INTRODUCING SUBSTITUENTS INTO ALPHA,BETA-UNSATURATED KETONE AND PROSTAGLANDIN COMPOUND SYNTHESIS METHOD UTILIZING SAME NAT CT GERIATRICS & GERONTOLOGY (JP) 2023-08-30 EP disclosed
EP-0198634-A2 Quaternized tellurium salt fog inhibiting agents for silver halide photography EASTMAN KODAK COMPANY (a New Jersey corporation) (US) 1986-10-22 EP disclosed
EP-0192466-A2 Novel chalcogen heterocycles, processes for their preparation, and articles containing such heterocycles EASTMAN KODAK COMPANY (a New Jersey corporation) (US) 1986-08-27 EP disclosed
US-4607000-A Amido substituted divalent chalcogenide fog inhibiting agents for silver halide photography EASTMAN KODAK COMPANY (US) 1986-08-19 US disclosed
US-4576905-A Photographically useful chalcogenazoles, chalcogenazolines, and chalcogenazolinium and chalcogenazolium salts EASTMAN KODAK COMPANY (US) 1986-03-18 US disclosed
EP-0138362-A2 Photographic materials containing chalcogenazoles, chalcogenazolines and chalcogenazolinium and chalcogenazolium salts EASTMAN KODAK COMPANY (a New Jersey corporation) (US) 1985-04-24 EP disclosed
EP-0136847-A2 Photographically useful chalcogenazolylidene and chalcogenazolium dyes and methods for their preparation EASTMAN KODAK COMPANY (a New Jersey corporation) (US) 1985-04-10 EP disclosed
EP-0132165-A1 Adsorbable alkynyl substituted heterocyclic quaternary ammonium salts and applications thereof to silver halide photography EASTMAN KODAK COMPANY (a New Jersey corporation) (US) 1985-01-23 EP disclosed
US-4471044-A Silver halide emulsions and photographic elements containing adsorbable alkynyl substituted heterocyclic quaternary ammonium salts EASTMAN KODAK COMPANY (US) 1984-09-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12128033-B2 Synthetic methods for preparation of 4-(2-chloro-4-methoxy-5-methylphenyl)-n-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-n-prop-2-ynyl-1,3-thiazol-2-amine CYP21A2, NR5A1, HSD3B1 CA2 1057/4885CA1 2381/4885ACHE 4537/4885
US-20240238257-A1 SYNTHETIC METHODS FOR PREPARATION OF 4-(2-CHLORO-4-METHOXY-5-METHYLPHENYL)-N-[(1S)-2-CYCLOPROPYL-1-(3-FLUORO-4-METHYLPHENYL)ETHYL]-5-METHYL-N-PROP-2-YNYL-1,3-THIAZOL-2-AMINE CYP21A2, NR5A1, HSD3B1 CA2 1256/4885CA1 2724/4885ACHE 4592/4885
US-20230286932-A1 SYNTHETIC METHODS FOR PREPARATION OF 4-(2-CHLORO-4-METHOXY-5-METHYLPHENYL)-N-[(1S)-2-CYCLOPROPYL-1-(3-FLUORO-4-METHYLPHENYL)ETHYL]-5-METHYL-N-PROP-2-YNYL-1,3-THIAZOL-2-AMINE CYP21A2, NR5A1, HSD3B1 CA2 1256/4885CA1 2724/4885ACHE 4592/4885
US-12582634-B2 Synthetic methods for preparation of 4-(2-chloro-4-methoxy-5-methylphenyl)-n-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-n-prop-2-ynyl-1,3-thiazol-2-amine CYP21A2, CYP11B1, NR5A1 CA2 773/4885CA1 1373/4885ACHE 4042/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.